Affymetrix, Inc. (NASDAQ:AFFX)
Engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets and create tools that advances the understanding of the molecular basis of life.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Recs
I don't really remember how Affymetrix got into my data base. It's not a biopharma and I don't really know the first thing about equipment for genetic analysis. Maybe I got it mixed up with Affymax once. Regardless, I've been keeping an eye on their sales and their share price for a few years now and I've had some success on CAPS picks when one becomes discordant with the other.
Revenues have been stable the last few quarters but the cash burn was substantially lower in Q2. The share price was recently as high as 5.4 but has declining after the company announced a 109M debt financing. I'm not a big fan of debt, but I've seen many companies in this sector use it as an effective tool for growth. The share price could easily decline to recent lows of 4, but I believe that ultimately the stock will remain range-bound and I'll be able to close the pick over 5.
Recs
Chart Play
Recs
Chart Play
Recs
Affy chips are paving the way for personalized medicine.
Recs
this is going to 5$!
Recs
valuation, great potential
Recs
Deeply oversold and about to return to profitability so the stock should get above $6 in the next 3-12 months.
Recs
Insider buys. Growth sector.
Cash flows do not show the grim picture than accounting does.
Recs
strong buy
Recs
Knocked down quite badly today, but genetic testing is ramping up. As it becomes more common for companies to turn to this, AFFX will continue to grow.
Recs
great tech signs
Recs
nih grant
Recs
I'm counting on AFFX to innovate in the field of Genetic mapping, and bring their prices down to the same level or at least a more fitting level for their products. Plus, with the other Genetic Mapping companies in the game, I think they will all benefit in the next five years or so.
Recs
semiconductor sector starting to turn up.
Recs
can't get any lower
Recs
An out-of-favor provider of research tools and systems for genetic analysis that is poised to regain investor favor due to the need for innovation in biotech and pharma industry.
Recs
the stock has been beaten up and the chart is positive
Recs
Rule Breaker, Insiders, Sector bet
Recs
potential to do well in future
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 57 : 1 2 3 Next »